Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tempero Pharmaceuticals Inc.

www.temperopharma.com

Latest From Tempero Pharmaceuticals Inc.

AZ Spins Out Entasis To Tackle Resistant Infections

AstraZeneca has, after a long gestation, given birth to the antibiotic developer Entasis Therapeutics: in early July the biotech debuted with $40 million in funding from AZ alone, and a portfolio of the drugmaker’s early-stage antibiotic candidates. It emerges as the debate about incentivizing antibiotics R&D intensifies amid growing concerns about antibiotic-resistant bacteria.

BioPharmaceutical Strategy

Epigenetic Modifiers Take Center Stage, Big Pharma Takes Notice

Epigenetic modifiers are targeting a widening range of indications as growing knowledge of the underlying biology enables improved agents and therapeutic strategies. Nonetheless, issues of selectivity, toxicity, and finding adequate biomarkers still prevent the field from reaching its full potential.

BioPharmaceutical Deals

GSK Spins Out Pain Assets Into Convergence

The first spin-out company to result from GlaxoSmith-Kline PLC’s exit from key CNS areas including pain and depression was announced on October 4. UK-based Convergence Pharmaceuticals Ltd. raised $35.4 million (£22.4 million) in one of Europe’s largest Series A rounds.
BioPharmaceutical Strategy

Best of the Blog: START-UP May/June 2009

Our favorite blog posts from May and June related to stories not covered elsewhere in this issue of Start-Up.
Business Strategies Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Tempero Pharmaceuticals Inc.
  • Senior Management
  • Paul-Peter Tak, MD, CEO
    Andrea Itano, PhD, CSO
    Beverly Carr, CBO
  • Contact Info
  • Tempero Pharmaceuticals Inc.
    Phone: (617) 374-8830
    200 Technology Sq.
    Ste. 602
    Cambridge, MA 02139
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register